Interpreting the adverse esophageal and colorectal findings in the Cancer Risk in Vegetarians Consortium

British Journal of Cancer · Published 2026-06-23 · DOI 10.1038/s41416-026-03527-6

Free full text

Authors (1)

Naman K. Shah

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shah, N. (2026). Interpreting the adverse esophageal and colorectal findings in the Cancer Risk in Vegetarians Consortium. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03527-6

Related articles

• Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma · British Journal of Cancer · 2026 · Same journal
• High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression · British Journal of Cancer · 2026 · Same journal
• Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial · British Journal of Cancer · 2026 · Same journal
• Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells · British Journal of Cancer · 2026 · Same journal
• AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma · British Journal of Cancer · 2026 · Same journal
• Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies · British Journal of Cancer · 2026 · Same journal
• Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis · British Journal of Cancer · 2026 · Same journal
• Signatures of micropeptides encoded by lncRNAs in cancer progression and metastasis · British Journal of Cancer · 2026 · Same journal
• Can national lung cancer screening programs be implemented without exacerbating social disparities? · British Journal of Cancer · 2026 · Same journal
• Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial · British Journal of Cancer · 2026 · Same journal